$EXAS Recent News My long, profitable relationship with

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 12:08 PM

$EXAS Recent News

My long, profitable relationship with Exact Sciences 12:01 a.m. Today - Kirk Spano
Fifteen stocks for 2015, part 1 10:36 a.m. Jan. 9, 2015 - The Trading Deck
The ‘next great investing columnist’ looks back — and ahead 12:04 p.m. Dec. 31, 2014 - The Trading Deck
5 stocks to watch 10:46 a.m. Nov. 26, 2014 - The Trading Deck
A fairly valued market may mean gains in 2015 4:57 a.m. Nov. 24, 2014 - MarketWatch
U.S. benchmarks hesitate at major resistance 9:26 a.m. Oct. 20, 2014 - Michael Ashbaugh
S&P 500, Nasdaq suffer worst weekly loss since May 2012 3:26 p.m. Oct. 10, 2014 - Anora Mahmudova
Exact Sciences shares rise on cancer-test reimbursement 8:06 a.m. Oct. 10, 2014 - Chelsey Dulaney
Skullcandy gains on upgrade,Tesla reverses gains 1:37 p.m. Aug. 12, 2014 - Sue Chang
FDA approves DNA test for colon cancer 6:07 a.m. Aug. 12, 2014 - Joseph Walker
Puma Biotech’s blast-off is not a typical short squeeze 11:10 a.m. July 23, 2014 - Tomi Kilgore
6 stocks to watch 2:41 p.m. July 16, 2014 - The Trading Deck
Fourteen stocks for 2014 halftime report 10:49 a.m. July 8, 2014 - The Trading Deck
A very Exact opportunity in biotech 11:06 a.m. April 4, 2014 - The Trading Deck
Investors let air out of biotech amid overheating, pricing concerns 12:42 p.m. March 21, 2014 - Russ Britt
Mayo takes the rap for Exact's test leak, but stock gain remains a puzzle 3:48 p.m. March 19, 2014 - Russ Britt
Company's plan to release positive cancer screening results goes awry 11:24 a.m. March 19, 2014 - Russ Britt
Fourteen stocks for 2014 12:02 a.m. Jan. 7, 2014 - Kirk Spano
Biotech volatility can mean danger or opportunity 12:09 p.m. Oct. 23, 2013 - The Trading Deck
Three calls with big upside 12:14 p.m. Sept. 25, 2013 - The Trading Deck

VolitionRx: The Future Of Cancer Screening 9:18 a.m. Feb. 12, 2015 - Seeking Alpha
Swiss diagnostics firm acquires CRC molecular blood test 7:57 a.m. Feb. 12, 2015 - Seeking Alpha
5 Stocks With Ugly Sales Growth — RNA IFT CBMG CCXI EXAS 2:45 a.m. Feb. 9, 2015 - InvestorPlace.com
'Fast Money' Recap: How to Trade in a Gyrating Stock Market 5:00 a.m. Feb. 7, 2015 - TheStreet.com
Check-Cap on deck for IPO 12:29 p.m. Feb. 6, 2015 - Seeking Alpha
5 Stocks With Bad Sales Growth — RNA IFT CBMG CCXI EXAS 4:30 a.m. Feb. 2, 2015 - InvestorPlace.com
5 Stocks With Poor Sales Growth — RNA IFT CBMG CCXI EXAS 1:15 a.m. Jan. 26, 2015 - InvestorPlace.com
Exact Sciences' Puzzling Early Launch Trajectory Update For Cologuard - An Analysis 6:30 a.m. Jan. 21, 2015 - Seeking Alpha
5 Stocks With Crummy Sales Growth — RNA IFT CBMG CCXI EXAS 2:30 a.m. Jan. 20, 2015 - InvestorPlace.com
A Rare Bogey for Barron’s 12:45 a.m. Jan. 17, 2015 - Barrons.com
Biggest Movers in Healthcare Stocks Now – LH GSK PCRX ACHN 12:30 p.m. Jan. 15, 2015 - InvestorPlace.com
The Liquid Biopsy Will Boost Revenue For Sequenom And Illumina 11:36 a.m. Jan. 15, 2015 - Seeking Alpha
Why You Shouldn't Bet Against Exact Sciences (EXAS) Stock - Tale of the Tape 8:40 a.m. Jan. 13, 2015 - Zacks.com
Exact Sciences reports Cologuard volume for 2014 12:58 p.m. Jan. 12, 2015 - Seeking Alpha
5 Stocks With Bad Sales Growth — RNA IFT CBMG CCXI EXAS 1:45 a.m. Jan. 12, 2015 - InvestorPlace.com
Interesting EXAS Put And Call Options For February 20th 11:05 a.m. Jan. 6, 2015 - TheStreet.com
UPDATE: Lake Street Initiates Coverage On EXACT Sciences 10:36 a.m. Jan. 5, 2015 - benzinga.com
Final Medicare reimbursement set for Cologuard 9:49 a.m. Jan. 2, 2015 - Seeking Alpha
Hottest Healthcare Stocks Now – ISIS NBIX CLDX EXAS 6:15 a.m. Dec. 26, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – ACHN EXAS CBPO ABMD 7:30 a.m. Dec. 22, 2014 - InvestorPlace.com

Exact Sciences Names Michael S. Wygza to its Board of Directors 10:32 a.m. Feb. 11, 2015 - BusinessWire - BZX
Exact Sciences to Participate in Leerink Global Healthcare Conference 4:31 p.m. Feb. 5, 2015 - BusinessWire - BZX
Exact Sciences Announces Norton Healthcare to Adopt Cologuard 3:30 p.m. Jan. 28, 2015 - BusinessWire - BZX
Exact Sciences Offers Update on Cologuard’s® Early Launch Trajectory 9:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Exact Sciences Names Scott Coward as General Counsel 10:18 a.m. Jan. 9, 2015 - BusinessWire - BZX
Exact Sciences to participate in J.P. Morgan Healthcare Conference 4:30 p.m. Jan. 6, 2015 - BusinessWire - BZX
Exact Sciences: Additional Update on CMS Reimbursement for Cologuard® 8:00 a.m. Jan. 2, 2015 - BusinessWire - BZX
Technical Commentary on Pharma Stocks -- AstraZeneca, Horizon Pharma, Valeant Pharma Intl., Exact Sciences, and Novo Nordisk 8:40 a.m. Dec. 29, 2014 - PR Newswire - PRF
Update on CMS Reimbursement for Cologuard® 5:30 p.m. Dec. 19, 2014 - BusinessWire - BZX
Exact Sciences Addresses CMS Reimbursement for Cologuard® 3:30 p.m. Dec. 19, 2014 - BusinessWire - BZX
Exact Sciences Announces Pricing of Public Offering of Common Stock 9:10 a.m. Dec. 16, 2014 - BusinessWire - BZX
Exact Sciences Announces Agreement to Sell 4,000,000 Common Shares 4:08 p.m. Dec. 15, 2014 - BusinessWire - BZX
Exact Sciences Announces Mercy Hospital St. Louis Now Offering Cologuard® 8:04 a.m. Dec. 2, 2014 - BusinessWire - BZX
Exact Sciences Announces Final Payment Decision for Cologuard® from the Centers for Medicare & Medicaid Services 12:43 p.m. Nov. 25, 2014 - BusinessWire - BZX
Cologuard® Wins Popular Science Magazine’s 2014 “Best of What's New” Award 12:30 p.m. Nov. 12, 2014 - BusinessWire - BZX
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics 9:05 a.m. Nov. 10, 2014 - PR Newswire - PRF
American Cancer Society Includes Exact Sciences’ Cologuard in Colorectal Cancer Prevention and Early Detection Guidelines 8:03 a.m. Nov. 6, 2014 - BusinessWire - BZX
Exact Sciences to Participate in November Conferences 4:33 p.m. Nov. 5, 2014 - BusinessWire - BZX
Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard® 8:01 a.m. Oct. 29, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NMIXX Ignites Global Cinemas With SCREENX Concert

NMIXX Takes K-Pop To Cinemas Worldwide When it comes to turning audacious ideas into reality, CJ 4DPLEX is making noise by blasting NMIXX's concert right onto the big screens across the globe. We're not just talking about a regular cinema trip here—no popcorn flick nonsense. On November 29, get ready for a ride with the NMIXX 1ST WORLD TOUR?EPISODE 1: ZERO...

Claus for a Cause: Respecting Heroes with Holiday Cheer

An Unforgettable Holiday Season Veterans Day isn't just a date on the calendar—it's an opportunity to pause and offer genuine thanks to those who've served with honor. This year, as the holiday season rolls around, Gemmy Industries' Claus for a Cause collection is redefining how we show our appreciation. These aren't your ordinary inflatables; they come with a purpose...

MOUZ Triumphs at IEM-Beijing 2026, Powered by AutoFull

A Showdown in Beijing: Esports at Its Peak IEM Beijing 2026 wrapped up on November 8, lighting up the Bloomage Biotech•Biohyalux ECM Arena with some high-octane Counter-Strike 2 matches. In a region that's nothing short of a digital battleground, Team MOUZ clinched the crown. And yeah, they didn't just do it solo; they did it seated in style on AutoFull chairs, the...

Compass Faces Legal Heat Over Accelerated Merger Closing

A Storm Brews Over Compass's Hasty Merger Actions Ah, the unpredictable world of mergers and acquisitions, where timelines often feel like they're written in sand, easy to shift with the tides. Today, we untangle the drama swirling around Compass, Inc. (NYSE: COMP) and its speedy merger with Anywhere Real Estate, a tale that's leaving investors with a taste that's more...

Hansa Bolsters Financials with SERB Deal, Eyes Growth

Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...

Nevada Organic Phosphate's Latest Drilling Success Insight

Striking Continuity in Murdock Mountain Drilling Ah, the thrill when a junior explorer delivers juicy results! Nevada Organic Phosphate (CSE: NOP) just scored big with its latest drilling escapades, adding flesh to the bone of this Murdock Mountain project. The company's confidence rides high with the beat as core samples from MM26-14 and MM26-15 drilled into the...

Gilat's Revenue Dip Spurs Legal Scrutiny for Investors

Gilat Satellite's Surprise Revenue Shortfall If anybody thought the satellite business was all about science fiction-esque technology, here's a reality check: when earnings don't meet expectations, shareholders get jittery. This seems to be exactly what's happening with Gilat Satellite Networks Ltd. (NASDAQ: GILT). After twice reaffirming their fiscal 2026 revenue...

Premium Guard Inc. Secures 2027 Top Supplier Honor

This ain't your everyday pat on the back—when Premium Guard Inc. (PGI) snagged the 2027 Top Supplier title from MEMA Aftermarket Suppliers and aftermarketNews, it was a nod to their hustle in the wild world of automotive. Yeah, the guys in Memphis are overachievers, consistently nudging the envelope of car parts. Why Premium Guard Stands Out Let’s be real, it’s not...

IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Tarlton's $9.5M Overhaul Boosts The Muny in 2027

Now, here's something that might grab your attention: a $9.5 million facelift for America's oldest outdoor musical theater, The Muny, thanks to Tarlton Corporation. They're not just giving it a fresh coat of paint—they're diving headfirst into a full-scale renovation to keep those summertime tunes in St. Louis' Forest Park as enchanting as ever. The Muny's New Lease on...